60
Participants
Start Date
November 20, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2030
Continuous Denosumab
Active comparator: persistent treatment of denosumab.
Administer zoledronate and denosumab on an alternating schedule
In the experimental group, zoledronic acid was administered for one year, followed by two years of denosumab. This cycle was repeated, with the regimen concluding with one year of zoledronic acid.
National Taiwan University Hospital, Yunlin branch, Douliu
National Taiwan University Hospital
OTHER